开放标签临床试验扩展:塞拉德尔帕治疗原发性胆汁性胆管炎患者的两年安全性和有效性结果
这项开放标签、国际长期扩展研究纳入完成塞拉德尔帕先导研究的原发性胆汁性胆管炎患者,每日口服5或10毫克,分析长达2年的安全性和有效性。106例患者中未见严重治疗相关不良事件,53例完成2年治疗者复合终点应答率从第1年66%升至第2年79%,碱性磷酸酶正常化率从26%升至42%。
要点
- 106例患者接受塞拉德尔帕治疗长达2年,未观察到严重治疗相关不良事件。
- 53例完成2年治疗者复合终点应答率从第1年66%升至第2年79%。
- 碱性磷酸酶正常化率从第1年26%升至第2年42%。
核心结论
- 塞拉德尔帕是安全的,并显著改善原发性胆汁性胆管炎患者的胆汁淤积和肝损伤生化标志物,这些效应在第二年维持或改善。
研究设计与样本
- 开放标签、国际长期扩展研究,患者为完成塞拉德尔帕先导研究的原发性胆汁性胆管炎患者,继续每日口服塞拉德尔帕5或10毫克,允许因安全性或耐受性调整剂量。
- 主要分析为安全性,次要有效性分析考察胆汁淤积和肝损伤的生化标志物,安全性和有效性数据分析至2年。
- 研究因一项同期非酒精性脂肪性肝炎研究中出现的意外组织学发现而提前终止,这些发现随后被确定早于治疗发生。
主要发现
- 106例接受塞拉德尔帕治疗长达2年的患者中未观察到严重治疗相关不良事件。
- 有4例因安全性停药,其中1例可能与塞拉德尔帕相关。
- 53例完成2年塞拉德尔帕治疗的患者中,复合终点应答率从第1年66%升至第2年79%。
- 53例完成2年治疗的患者中,碱性磷酸酶正常化率从第1年26%升至第2年42%。
- 基线胆红素升高的患者中,43%在第2年达到正常化。
关键数值与推荐
- 复合终点定义为碱性磷酸酶低于1.67倍正常值上限、碱性磷酸酶较基线下降至少15%、且总胆红素不超过正常值上限。
临床怎么用
- 原文未据此给出推荐。
局限性
- 研究因一项同期非酒精性脂肪性肝炎研究中出现的意外组织学发现而提前终止,这些发现随后被确定早于治疗发生。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Seladelpar is a potent and selective peroxisome proliferator-activated receptor-δ agonist that targets multiple cell types involved in primary biliary cholangitis (PBC), leading to anti-cholestatic, anti-inflammatory and anti-pruritic effects. AIMS: To evaluate the long-term safety and efficacy of seladelpar in patients with PBC. METHODS: In an open-label, international, long-term extension study, patients with PBC completing seladelpar lead-in studies continued treatment. Seladelpar was taken orally once daily at doses of 5 or 10 mg with dose adjustment permitted for safety or tolerability. The primary analysis was for safety and the secondary efficacy analysis examined biochemical markers of cholestasis and liver injury. The study was terminated early due to the unexpected histological findings in a concurrent study for non-alcoholic steatohepatitis, which were subsequently found to predate treatment. Safety and efficacy data were analysed through 2 years. RESULTS: There were no serious treatment-related adverse events observed among 106 patients treated with seladelpar for up to 2 years. There were four discontinuations for safety, one possibly related to seladelpar. Among 53 patients who completed 2 years of seladelpar, response rates increased from years 1 to 2 for the composite endpoint (alkaline phosphatase [ALP] <1.67 × ULN, ≥15% decrease in ALP, and total bilirubin ≤ULN) and ALP normalisation from 66% to 79% and from 26% to 42%, respectively. In those with elevated bilirubin at baseline, 43% achieved normalisation at year 2. CONCLUSIONS: Seladelpar was safe, and markedly improved biochemical markers of cholestasis and liver injury in patients with PBC. These effects were maintained or improved throughout the second year. CLINICALTRIALS: gov: NCT03301506; Clinicaltrialsregister.eu: 2017-003910-16.
引用
- Mayo MJ, Vierling JM, Bowlus CL, et al. Open-label, clinical trial extension: Two-year safety and efficacy results of seladelpar in patients with primary biliary cholangitis. Aliment Pharmacol Ther. 2023. PMID: 37904314. doi:10.1111/apt.17755
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。